What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

Annals of Oncology

Volumn 29, Issue 5, 2018, Pages 1249-1257

  Vale, Claire L ^a   Fisher, D J ^a   White, I R ^a   Carpenter, J R ^a   Burdett, S ^a   Clarke, N W ^b   Fizazi, K ^c   Gravis, G ^d   James, N D ^e,f   Mason, M D ^g   Parmar, M K B ^a   Rydzewska, L H ^a   Sweeney, C J ^h   Spears, M R ^a   Sydes, M R ^a   Tierney, J F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Abiraterone; Androgen deprivation therapy; Docetaxel; Network meta analysis; Prostate cancer; Systematic review

Indexed keywords

ABIRATERONE ACETATE; CELECOXIB; DOCETAXEL; PREDNISOLONE; PREDNISONE; ZOLEDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC AGENT; PREDNISOLONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SURVIVAL; CORRELATIONAL STUDY; DRUG EFFECT; DRUG EFFICACY; FAILURE FREE SURVIVAL; HUMAN; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; BLOOD; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; MALE; MORTALITY; NETWORK META-ANALYSIS; PATHOLOGY; PROSTATE TUMOR;

ABIRATERONE ACETATE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOCETAXEL; HUMANS; MALE; NETWORK META-ANALYSIS; PREDNISOLONE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ZOLEDRONIC ACID;

EID: 85045121224     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy071     Document Type: Article

References (24)

1. Rydzewska LHM, Burdett S, Vale CL et al. Adding abiraterone to androgen deprivation therapy inmen withmetastatic hormone-sensitive prostate cancer: a systematic review andmeta-analysis. Eur J Cancer 2017; 84: 88-101
2. Vale CL, Burdett S, Rydzewska LH et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol. 2016; 17(2): 243-256
3. MasonMD, ClarkeNW, James ND et al. Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017; 35(14): 1530-1541
4. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521): 897-900
5. White IR. Network meta-analysis. Stata J 2015; 15: 951-985
6. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8(1): 16
7. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
8. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. BMJ 2013; 346: f1798
9. Jackson D, White IR, Price M et al. Borrowing of strength and study weights in multivariate and network meta-analysis. Stat Methods Med Res 2017; 26(6): 2853-2868
10. Salanti G, Ades AE, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64(2): 163-171
11. Sydes M, Parmar M, James N et al. Issues in applying multi-arm multistage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10(1): 39
12. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377(4): 338-351
13. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387(10024): 1163-1177
14. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl JMed 2017; 377(4): 352-360
15. Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in meta-static hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8): 737-746
16. Rydzewska L, Tierney J, Burdett S et al. Systematic review and metaanalysis of the effects of abiraterone for hormone-sensitive metastatic prostate cancer. PROSPERO 2017: CRD42017058300. 2017; http://www. crd.york.ac.uk/PROSPERO/display_record.asp? ID=CRD42017058300 (1 March 2018, date last accessed)
17. Sydes MR, Spears MR, Mason MD et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29(5): 1235-1248
18. Feyerabend S, Saad F, Li T et al. Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic 'hormone-sensitive' prostate cancer. Ann Oncol 2017; 28(Suppl 5): Abstr 803P
19. Wallis CJD, Klaassen Z, Bhindi B et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol 2017 Oct 13 [Epub ahead of print], doi: 10.1016/j.eururo.2017.10.002
20. Vale C, Fisher D, Tierney J et al. Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol 2018; 73: e49-e50
21. Smith MR, Halabi S, Ryan CJ et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014; 32(11): 1143-1150
22. Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016; 70(2): 256-262
23. Sweeney C, Chen Y, Liu G et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann Oncol 2016; 27(Suppl 6): 243-265
24. Kamba T, Kamoto T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H et al. A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naïve prostate cancer patients with bone metastases: results of ZAPCA study. J Clin Oncol 2015; 33(Suppl 7): A150